Defining treatment failure in severe osteoporosis

被引:8
作者
Confavreux, Cyrille B. [1 ,2 ]
Paccou, Julien [3 ]
David, Claire [4 ]
Mehsen, Nadia [5 ]
Leboime, Ariane [6 ]
Thomas, Thierry [7 ,8 ]
机构
[1] INSERM, U831, F-69008 Lyon, France
[2] Univ Lyon, Serv Rhumatol, Hosp Civils Lyon, Lyon, France
[3] CHU Hop Roger Salengro, Dept Univ Rhumatol, Lille, France
[4] CHU Hop Sud, Serv Rhumatol, Rennes, France
[5] CHU Pellegrin, Serv Rhumatol, Bordeaux, France
[6] Univ Paris 05, Hop Cochin, Serv Rhumatol B, Paris, France
[7] CHU St Etienne, INSERM, U890, F-42055 St Etienne, France
[8] CHU St Etienne, Serv Rhumatol, F-42055 St Etienne, France
关键词
Osteoporosis; Treatment; Adherence; Treatment failure; Inadequate response; BONE-MINERAL DENSITY; VERTEBRAL FRACTURE ASSESSMENT; ISCD OFFICIAL POSITIONS; POSTMENOPAUSAL OSTEOPOROSIS; TREATMENT PERSISTENCE; STRONTIUM RANELATE; BISPHOSPHONATE THERAPY; NONVERTEBRAL FRACTURES; VITAMIN-D; WOMEN;
D O I
10.1016/S1297-319X(10)70008-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The management of postmenopausal osteoporosis has benefited from the recent introduction of several new drug classes and is now well standardized However none of the available osteoporosis drugs completely abolishes the occurrence of fractures Therefore criteria are needed to determine when the occurrence of a fracture during treatment indicates failure to respond to the drug Such criteria would Improve patient management A panel of national osteoporosis experts was convened to discuss data from a literature review on severe osteoporosis (Osteoporosis Diagnosis and Surveillance of SEvErity ODISSEE) The experts reached a consensus that an inadequate response to treatment for postmenopausal osteoporosis is the occurrence in a patient with severe osteoporosis adequate calcium and vitamin D intakes and good treatment adherence of any of the following incident major fracture within the first treatment year more than one minor insufficiency fracture or a bone mineral density decrease by at least the smallest significant amount (0 03 g/cm(2)) after 5 years or earlier in the event of a minor fracture (C) 2010 Societe francaise de rhumatologie Published by Elsevier Masson SAS All rights reserved
引用
收藏
页码:S128 / S132
页数:5
相关论文
共 43 条
[1]   Fracture incidence and characterization in patients on osteoporosis treatment: The ICARO study [J].
Adami, Silvano ;
Isaia, Giancarlo ;
Luisetto, Giovanni ;
Minisola, Salvatore ;
Sinigaglia, Luigi ;
Gentilella, Raffaella ;
Agnusdei, Donato ;
Iori, Nicoletta ;
Nuti, Ranuccio .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (10) :1565-1570
[2]   Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].
Black, Dennis M. ;
Delmas, Pierre D. ;
Eastell, Richard ;
Reid, Ian R. ;
Boonen, Steven ;
Cauley, Jane A. ;
Cosman, Felicia ;
Lakatos, Peter ;
Leung, Ping Chung ;
Man, Zulema ;
Mautalen, Carlos ;
Mesenbrink, Peter ;
Hu, Huilin ;
Caminis, John ;
Tong, Karen ;
Rosario-Jansen, Theresa ;
Krasnow, Joel ;
Hue, Trisha F. ;
Sellmeyer, Deborah ;
Eriksen, Erik Fink ;
Cummings, Steven R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822
[3]   Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience [J].
Briot, K. ;
Ravaud, P. ;
Dargent-Molina, P. ;
Zylberman, M. ;
Liu-Leage, S. ;
Roux, C. .
OSTEOPOROSIS INTERNATIONAL, 2009, 20 (04) :625-630
[4]   Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate [J].
Bruyere, Olivier ;
Roux, Christian ;
Detilleux, Johann ;
Slosman, Daniel O. ;
Spector, Tim D. ;
Fardellone, Patrice ;
Brixen, Kim ;
Devogelaer, Jean-Pierre ;
Diaz-Curiel, Manuel ;
Albanese, Carlina ;
Kaufman, Jean-Marc ;
Pors-Nielsen, Stig ;
Reginster, Jean-Yves .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (08) :3076-3081
[5]   The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008
[6]   Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture [J].
Chapurlat, R. D. ;
Duboeuf, F. ;
Marion-Audibert, H. O. ;
Kalpakcioglu, B. ;
Mitlak, B. H. ;
Delmas, P. D. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (08) :1189-1195
[7]   Drug insight: bisphosphonates for postmenopausal osteoporosis [J].
Chapurlat, RD ;
Delmas, PD .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (04) :211-219
[8]   Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial [J].
Chapurlat, RD ;
Palermo, L ;
Ramsay, P ;
Cummings, SR .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (07) :842-848
[9]   Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis [J].
Chesnut, CH ;
Skag, A ;
Christiansen, C ;
Recker, R ;
Stakkestad, JA ;
Hoiseth, A ;
Felsenberg, D ;
Huss, H ;
Gilbride, J ;
Schimmer, RC ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1241-1249
[10]   Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study [J].
Cooper, A. ;
Drake, J. ;
Brankin, E. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) :896-905